Pfizer Inc. (NYSE:PFE) is IMS Capital Management’s 7th Largest Position

IMS Capital Management grew its position in Pfizer Inc. (NYSE:PFEGet Rating) by 451.4% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 65,134 shares of the biopharmaceutical company’s stock after buying an additional 53,321 shares during the quarter. Pfizer accounts for 2.2% of IMS Capital Management’s holdings, making the stock its 7th largest holding. IMS Capital Management’s holdings in Pfizer were worth $3,415,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in PFE. Aureus Asset Management LLC bought a new position in shares of Pfizer in the 4th quarter worth $221,000. Nuveen Asset Management LLC raised its position in shares of Pfizer by 18.0% in the 4th quarter. Nuveen Asset Management LLC now owns 28,086,667 shares of the biopharmaceutical company’s stock worth $1,658,518,000 after acquiring an additional 4,278,167 shares in the last quarter. Gordian Capital Singapore Pte Ltd bought a new position in shares of Pfizer in the 4th quarter worth $237,000. Odey Asset Management Group Ltd raised its position in shares of Pfizer by 85.7% in the 4th quarter. Odey Asset Management Group Ltd now owns 130,000 shares of the biopharmaceutical company’s stock worth $7,677,000 after acquiring an additional 60,000 shares in the last quarter. Finally, Banco de Sabadell S.A raised its position in shares of Pfizer by 16.7% in the 4th quarter. Banco de Sabadell S.A now owns 47,358 shares of the biopharmaceutical company’s stock worth $2,797,000 after acquiring an additional 6,793 shares in the last quarter. 67.90% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts recently issued reports on PFE shares. UBS Group set a $59.00 target price on Pfizer in a research report on Thursday, September 1st. Morgan Stanley reduced their target price on Pfizer from $52.00 to $49.00 and set an “equal weight” rating on the stock in a research report on Friday, July 8th. SVB Leerink reduced their target price on Pfizer from $55.00 to $53.00 and set a “market perform” rating on the stock in a research report on Friday, July 29th. Berenberg Bank set a $44.00 target price on Pfizer in a research report on Wednesday, September 14th. Finally, Barclays set a $50.00 target price on Pfizer in a research report on Thursday, September 1st. Nine equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Pfizer presently has a consensus rating of “Moderate Buy” and an average price target of $57.00.

Pfizer Stock Up 1.5 %

Shares of PFE opened at $44.57 on Friday. Pfizer Inc. has a 52 week low of $40.94 and a 52 week high of $61.71. The company has a quick ratio of 1.20, a current ratio of 1.42 and a debt-to-equity ratio of 0.39. The company has a market capitalization of $250.14 billion, a price-to-earnings ratio of 8.72, a PEG ratio of 0.54 and a beta of 0.70. The stock’s 50-day moving average price is $48.40 and its 200-day moving average price is $50.33.

Pfizer (NYSE:PFEGet Rating) last issued its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.95 by $0.09. The company had revenue of $27.74 billion for the quarter, compared to the consensus estimate of $26.20 billion. Pfizer had a return on equity of 43.18% and a net margin of 28.92%. Pfizer’s revenue for the quarter was up 46.8% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.07 earnings per share. On average, sell-side analysts predict that Pfizer Inc. will post 6.54 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 5th. Shareholders of record on Friday, November 4th will be given a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a yield of 3.59%. Pfizer’s dividend payout ratio is currently 31.31%.

Pfizer Profile

(Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

Further Reading

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEGet Rating).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.